1. Home
  2. Analysis
  3. Docetaxel
  4. Oncovin

Docetaxel and Oncovin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Docetaxel (docetaxel) and Oncovin (vincristine sulfate). Common drug interactions include acute hepatic failure among females.

The phase IV clinical study analyzes what interactions people have when they take Docetaxel and Oncovin. It is created by eHealthMe based on reports of 15 people who take the same drugs from the FDA, and is updated regularly.

What is Docetaxel?

Docetaxel has active ingredients of docetaxel. eHealthMe is studying from 79,875 Docetaxel users. Check the latest studies of Docetaxel.

What is Oncovin?

Oncovin has active ingredients of vincristine sulfate. eHealthMe is studying from 6,667 Oncovin users. Check the latest studies of Oncovin.

On Aug, 01, 2026

15 people who take Docetaxel and Oncovin together, and have interactions are studied.

Docetaxel and Oncovin drug interactions.

What are the common drug interactions of Docetaxel and Oncovin, by gender? *:

female:

  1. Acute hepatic failure
  2. Papillary thyroid cancer
  3. Second primary malignancy (after getting cure a cancer, a new cancer development)
  4. Death
  5. Hepatitis b
  6. Multi-organ failure (multisystem organ failure)

male:

n/a

What are the common drug interactions of Docetaxel and Oncovin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Papillary thyroid cancer
  2. Second primary malignancy (after getting cure a cancer, a new cancer development)

20-29:

  1. Papillary thyroid cancer
  2. Second primary malignancy (after getting cure a cancer, a new cancer development)

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Hepatitis b
  2. Multi-organ failure (multisystem organ failure)

What are the existing conditions these people have? *

  1. Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 10 people, 66.67%
  2. Breast Cancer: 9 people, 60.00%
  3. Osteosarcoma (a cancerous (malignant) bone tumour): 3 people, 20.00%
  4. Metastases To Lung (cancer spreads to lung): 2 people, 13.33%
  5. Primary Mediastinal Large B-Cell Lymphoma (primary mediastinal large b-cell cancer of the lymph nodes): 1 person, 6.67%
  6. Osteosarcoma Metastatic (a cancerous (malignant) bone tumour can spreads to other parts): 1 person, 6.67%
  7. Hodgkin's Lymphoma (cancer originating from white blood cells): 1 person, 6.67%
  8. Burkitt Lymphoma (cancer of the lymphatic system): 1 person, 6.67%
  9. Breast Cancer Female: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Docetaxel and Oncovin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Docetaxel and Oncovin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Docetaxel:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Oncovin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Docetaxel and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Oncovin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on docetaxel and vincristine sulfate (the active ingredients of Docetaxel and Oncovin, respectively), and Docetaxel and Oncovin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.